TTRX logo

TTRX
Turn Therapeutics Inc

389
Mkt Cap
$94.22M
Volume
41,253.00
52W High
$26.50
52W Low
$2.57
PE Ratio
-23.53
TTRX Fundamentals
Price
$3.12
Prev Close
$3.20
Open
$3.11
50D MA
$3.71
Beta
1.15
Avg. Volume
20,144.10
EPS (Annual)
-$0.1152
P/B
15.93
Rev/Employee
$0.00
$104.21
Loading...
Loading...
News
all
press releases
Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results
Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results...
Business Wire·1d ago
News Placeholder
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX)
D. Boral Capital restated a "buy" rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday...
MarketBeat·8d ago
News Placeholder
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan...
Business Wire·9d ago
News Placeholder
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy
Turn Therapeutics (NASDAQ:TTRX) executives outlined the company's focus on inflammatory skin disease and provided updates on its lead topical candidate, GX-03, during a presentation at an...
MarketBeat·1mo ago
News Placeholder
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment...
Business Wire·1mo ago
News Placeholder
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief...
Business Wire·2mo ago
News Placeholder
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday...
MarketBeat·2mo ago
News Placeholder
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced...
Business Wire·3mo ago
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Upgraded to "Strong-Buy" at D Boral Capital
D Boral Capital upgraded shares of Turn Therapeutics to a "strong-buy" rating in a research report on Monday...
MarketBeat·3mo ago
<
1
2
...
>

Latest TTRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.